Aja Beckett quit her job after her weight-loss shot-tracking app, Shotsy, took off on Reddit.
Now, one type of weight-loss medication is proving helpful with another health issue. In a study published Feb. 12 in JAMA ...
Sales of Eli Lilly’s (LLY) blockbuster weight-loss drug Zepbound surged in the fourth quarter despite missing the company’s initial sales expectations. Zepbound sales reached $1.9 billion in ...
For example, Wegovy (a GLP-1 receptor agonist) and Zepbound (a dual agonist) are both FDA-approved specifically to treat weight loss, while Ozempic (another GLP-1 receptor agonist) is not FDA ...
In the glittering world of celebrity-endorsed weight loss transformations and viral before-and-after photos, a darker narrative is emerging from the shadows ...
Eli Lilly investors and analysts said they want to hear details from the company on how exactly it plans to grow U.S. sales ...
People taking weight-loss drugs say they are losing their sight. Science is trying to figure out why
open image in gallery A small percentage of patients taking weight loss and diabetes drugs like Ozempic and Zepbound have experienced vision loss. However, scientists they there is not an ...
Approximately 15.5 million Americans have been or currently are on injectable diabetes or weight-loss medications known as GLP-1 receptor agonists, including the popular name brands Ozempic, Wegovy, ...
Eli Lilly & Co. said Thursday that its Type 2 diabetes drug Mounjaro and its weight-loss and diabetes drug Zepbound drove a 45% increase in fourth-quarter revenue to $13.53 billion. The drugmaker ...
Investors are upset at a lack of clarity over the results of Wegovy successor CagriSema after trials published in December.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback